ArticleScience advances2022
Targeting OXPHOS de novo purine synthesis as the nexus of
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies.Cancer discovery · 2025Article
- Metabolic Signature ofJournal of personalized medicine · 2025Review
- Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias.Cell death discovery · 2025Review
- Perturbomics: CRISPR-Cas screening-based functional genomics approach for drug target discovery.Experimental & molecular medicine · 2025Review
- A Recent Overview of Molecular Pathways in Synthetic Lethality as a Proposed Valid Target in Oncology: Current Insights and Future Directions.Indian journal of surgical oncology · 2025Review
- The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.Neoplasia (New York, N.Y.) · 2024Review
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.JCI insight · 2024Article
- The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.Experimental hematology & oncology · 2024Article
- DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood advances · 2023Article
- CRISPR screening in hematology research: from bulk to single-cell level.Journal of hematology & oncology · 2023Review
- ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.Cancer letters · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Pu ZhangDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-1548-2087
Lindsey T BrintonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-4149-9384
Mehdi GharghabiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-8030-3121
Steven SherDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-3788-3228
Katie WilliamsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Matthew CannonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-1908-7292
Janek S WalkerDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-2049-1527
Daniel CanfieldDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Larry BeaverDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Casey B CempreDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Hannah PhillipsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-7764-6078
Xuyong ChenCenter for Childhood Cancer and Blood Diseases, Hematology/Oncology and BMT, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-5069-0896
Pearlly YanDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-1965-4920
Amy LehmanCenter for Biostatistics, The Ohio State University, Columbus, OH, USA.
Peggy ScherlePrelude Therapeutics, Wilmington, DE, USA.ORCID 0000-0003-0783-6815
Min WangPrelude Therapeutics, Wilmington, DE, USA.
Kris VaddiPrelude Therapeutics, Wilmington, DE, USA.
Robert BaiocchiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-1619-4853
Ruoning WangCenter for Childhood Cancer and Blood Diseases, Hematology/Oncology and BMT, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-9798-8032
Deepa SampathDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-4366-8436
Lapo AlinariDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
James S BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-4275-5562
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-6916-9400
The Ohio State University · USNationwide Children's Hospital · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MMetabolic programming in TH17 cell differentiationR01AI114581 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WANG, RUONING · 2015 to 2025
$3.6MMetabolic reprogramming of tumor microenvironment to maximize immunotherapy for pediatric cancersU01CA232488 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WANG, RUONING · 2018 to 2018
$3.4MModulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapyR01CA247941 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WANG, RUONING · 2021 to 2025
$2.4MTargeting NAMPT in Acute Myeloid LeukemiaR01CA223165 · NCI · OHIO STATE UNIVERSITY · PI LAPALOMBELLA, ROSA, MIMS, ALICE SCOTT · 2018 to 2022
$2.3MDecipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseasesR01AI175004 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Ruoning Wang · 2023 to 2026
$2.0MNCI NIH HHS P30 CA016058NCI NIH HHS R01 CA223165NCI NIH HHS R01 CA247941NCI NIH HHS U01 CA232488NIAID NIH HHS R01 AI114581NIAID NIH HHS R01 AI175004
Abstract
Using a genome-wide CRISPR screen, we identified
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.